Evidence map›Paper›PMID 38871947›Full record

ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

Impact of Prolonged Dual Antiplatelet Therapy After Bifurcation Percutaneous Coronary Intervention in Patients with High Ischemic Risk.

Dmitrii Khelimskii, Ivan Bessonov, Stanislav Sapozhnikov, Aram Badoyan, Aleksey Baranov, Mahmudov Mamurjon, Serezha Manukian, Ruslan Utegenov, Oleg Krestyaninov

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03450577 (International Prospective Register on Treatment of Coronary Artery Bifurcation Lesions), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03450577 recruitingnot on this map

International Prospective Register on Treatment of Coronary Artery Bifurcation Lesions

Typeobservational_patient_registrySponsorMeshalkin Research Institute of Pathology of CirculationRan2018 to 2026Enrolled5,000ConditionsCoronary Bifurcation LesionArmsPCI of bifurcation lesions
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dmitrii KhelimskiiMeshalkin National Medical Research Center, Ministry of Health of Russian Federation, 15 Rechkunovskaya st., Novosibirsk, 630055, Russian Federation. dkhelim@mail.ru.ORCID http://orcid.org/0000-0001-5419-913X
Ivan BessonovTyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 625026, Russian Federation.
Stanislav SapozhnikovTyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 625026, Russian Federation.
Aram BadoyanMeshalkin National Medical Research Center, Ministry of Health of Russian Federation, 15 Rechkunovskaya st., Novosibirsk, 630055, Russian Federation.
Aleksey BaranovMeshalkin National Medical Research Center, Ministry of Health of Russian Federation, 15 Rechkunovskaya st., Novosibirsk, 630055, Russian Federation.
Mahmudov MamurjonMeshalkin National Medical Research Center, Ministry of Health of Russian Federation, 15 Rechkunovskaya st., Novosibirsk, 630055, Russian Federation.
Serezha ManukianMeshalkin National Medical Research Center, Ministry of Health of Russian Federation, 15 Rechkunovskaya st., Novosibirsk, 630055, Russian Federation.
Ruslan UtegenovTyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 625026, Russian Federation.
Oleg KrestyaninovMeshalkin National Medical Research Center, Ministry of Health of Russian Federation, 15 Rechkunovskaya st., Novosibirsk, 630055, Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to evaluate the impact of prolonged dual antiplatelet therapy (DAPT) on clinical outcomes in patients undergoing percutaneous coronary interventions (PCI) for bifurcation coronary lesions.

methodsA total of 1000 patients who underwent PCI for coronary bifurcation lesions and had clinical follow-up were divided into two groups based on the duration of DAPT: DAPT > 12 months and DAPT ≤ 12 months). Patients who experienced a myocardial infarction, required repeat PCI, or died within 1 year after the initial procedure were excluded.

resultsAmong the 1000 eligible patients, 394 patients received DAPT for > 12 months (39.4%). Most patients in our study presented with chronic coronary disease (61%). The majority of patients in our study (62.8%) had a low bleeding risk. The median follow-up duration was 35 months (interquartile range 20.6-36.5). There were no significant differences in the major adverse cardiovascular events (MACE) between groups of prolonged DAPT (> 12 month) and DAPT ≤ 12 months (18.8% vs. 14.9%, p = 0.11). Patients with clinical features of high ischemic risk (HIR) had a significantly increased risk of MACE (hazard ratio [HR] 1.92, 95% confidence interval [CI] 1.12-3.26, p = 0.015) when compared with patients without clinical features of HIR. Compared with DAPT ≤ 12 months, extended DAPT (> 12 months) did not improve outcomes in patients with clinical (HR 1.24, 95% CI 0.90-1.72, p = 0.19) and technical features (HR 1.04, 95% CI 0.67-1.63, p = 0.85) of HIR.

conclusionIn this multicenter real-world registry, administration of DAPT for more than 12 months in patients who have undergone PCI for bifurcation lesion is not associated with a reduced incidence of MACE in long-term follow-up. REGISTRATION: ClinicalTrials.gov identifier no. NCT03450577.

Indexed as

Dual Anti-Platelet TherapyPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsAgedCoronary Artery DiseaseFemaleHemorrhageHumansMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomePlatelet Aggregation Inhibitors

Identifiers

PMID38871947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.